IPG Photonics’ first quarter was met with a negative market reaction, reflecting concerns over declining sales and margin compression. Management pointed to stabilization in core business lines and highlighted “early traction in key areas that are central to our strategy,” according to CEO Mark Gitin. Notable factors behind the results included continued weakness in mature cutting applications, partially offset by growth in medical and advanced applications and the contribution from the cleanLASER acquisition. Gitin acknowledged lower demand in traditional materials processing, while CFO Tim Mammen cited sequential improvement in bookings, especially in e-mobility and micromachining.
Is now the time to buy IPGP? Find out in our full research report (it’s free).
IPG Photonics (IPGP) Q1 CY2025 Highlights:
- Revenue: $227.8 million vs analyst estimates of $225.1 million (9.6% year-on-year decline, 1.2% beat)
- Adjusted EPS: $0.31 vs analyst estimates of $0.22 (40.9% beat)
- Revenue Guidance for Q2 CY2025 is $225 million at the midpoint, below analyst estimates of $239.9 million
- Adjusted EPS guidance for Q2 CY2025 is $0.10 at the midpoint, below analyst estimates of $0.33
- EBITDA guidance for Q2 CY2025 is $23.5 million at the midpoint, below analyst estimates of $28.07 million
- Operating Margin: 0.8%, down from 7.6% in the same quarter last year
- Inventory Days Outstanding: 190, up from 180 in the previous quarter
- Market Capitalization: $2.88 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions IPG Photonics’s Q1 Earnings Call
- Ruben Roy (Stifel) asked about the drivers of strong bookings and growth in China’s e-mobility sector. CEO Mark Gitin cited “adjustable mode beam lasers and integrated scanning systems” as key differentiators in that market.
- Jim Ricchiuti (Needham & Company) questioned the expected timing of medical and micromachining product contributions. Gitin stated that the new urology system will see limited impact later this year with greater revenue contribution in 2026.
- Michael Feniger (Bank of America) inquired about the tariff’s effect on cost structure and competitive dynamics. CFO Tim Mammen explained that near-term gross margin impacts should decline as manufacturing shifts away from high-tariff regions.
- Scott Graham (Seaport Research Partners) sought clarification on manufacturing optimization and how moving production away from China will affect costs. Gitin responded that IPG’s global footprint allows for flexible realignment, minimizing tariff exposure with only minor increases in certain input costs.
- Keith Housum (Northcoast Research) probed the sustainability and composition of the book-to-bill ratio. Mammen indicated that medical orders have longer cycles, with most other segments remaining on short delivery timelines.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) the pace of tariff mitigation and supply chain reconfiguration, (2) revenue traction from new medical and micromachining products, and (3) stabilization or recovery in core cutting and welding applications. Execution on these priorities will be important in determining whether IPG can return to growth and margin expansion.
IPG Photonics currently trades at $68.84, up from $63.12 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
